Friedrich-Ebert-Krankenhaus Neumuenster GmbH
- Address
- Friesenstrasse 11, Innenstadt, 24534 Neumünster, Germany
Friedrich-Ebert-Krankenhaus Neumuenster GmbH - Oncology Research Center
Friedrich-Ebert-Krankenhaus Neumuenster GmbH is a leading clinical research institution specializing in oncology and hematology. The center demonstrates particular expertise in gastrointestinal cancers, lymphomas, and lung cancer, participating in pivotal Phase III trials that investigate innovative treatment approaches and optimize therapeutic strategies for cancer patients.
- Colorectal cancer research including preoperative chemotherapy strategies, post-resection therapy, and ctDNA-guided adjuvant treatment
- Lymphoma treatment optimization, including Hodgkin lymphoma and diffuse large B-cell lymphoma (DLBCL) with novel combination therapies
- Advanced non-small cell lung cancer studies and biosimilar development
The center's research portfolio reflects a comprehensive approach to cancer care, from early-stage disease management to metastatic settings. Notable contributions include participation in the PROTECTOR/FIRE-10 trial examining preoperative systemic therapy in advanced colon cancer, the FIRE-9 PORT trial investigating post-resection strategies in metastatic colorectal cancer, and the innovative CIRCULATE trial utilizing circulating tumor DNA (ctDNA) to guide adjuvant therapy decisions in stage II colon cancer. In hematologic malignancies, the institution participates in the HD21 trial comparing reduced-toxicity regimens for advanced Hodgkin lymphoma and studies evaluating acalabrutinib combinations in non-GCB DLBCL, demonstrating commitment to both efficacy and quality of life improvements for cancer patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 27 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Friedrich-Ebert-Krankenhaus Neumuenster GmbH
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Comparative Study of ABP 234 and Pembrolizumab in Patients with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Amgen Inc. | Phase I | Recruiting | Oct 2024 | — |
IMP list
lock Showing 1 of 27 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Capecitabine | 3 | Unknown | 2019-12-04 | 2025-04-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.